Form 4: Autonomix Director Cancels Stock Options

Autonomix Medical Director Lori Bisson cancelled 65,542 stock options without receiving any consideration, following a 1-for-20 reverse stock split.

Summary

• Lori Bisson, a Director of Autonomix Medical, Inc. (AMIX), cancelled a total of 65,542 stock options.
• This cancellation occurred on August 11, 2025.
• The cancelled options included 18,862 options with an exercise price of $26.56 and 46,680 options with an exercise price of $40.
• The cancellation was by mutual agreement between Ms. Bisson and the Company.
• Ms. Bisson received no consideration for the cancellation of these options.
• The share amounts and exercise prices of these options were previously adjusted due to a 1-for-20 reverse stock split effective October 25, 2024.
• Following these transactions, Ms. Bisson beneficially owns 47,930 derivative securities related to the first option type and 1,250 related to the second option type.

Sentiment

Score: 3

Explanation: The cancellation of a significant number of stock options by a director without consideration is generally a negative signal, as it implies a loss of potential future value for the insider and could suggest a lack of confidence in the stock's appreciation or a strategic move to reduce outstanding options without a clear benefit to the company or shareholders.

Negatives

• Director Lori Bisson cancelled 65,542 stock options without receiving any consideration, representing a loss of potential future value for the insider.
• The cancellation by mutual agreement without consideration could suggest a strategic decision, potentially indicating a lack of confidence in the options' future value or a restructuring of compensation.

Risks

• The cancellation of a significant number of director stock options without consideration could be interpreted negatively by investors, potentially signaling concerns about future stock performance or a lack of alignment between management and shareholder interests regarding option value.
• The reverse stock split (1-for-20 on October 25, 2024) indicates a prior effort to increase share price, which can sometimes be a sign of underlying financial challenges or efforts to maintain listing requirements.

Future Outlook

No forward-looking statements or guidance are provided.

Industry Context

This insider transaction is specific to Autonomix Medical, Inc. and its compensation structure, rather than reflecting broader industry trends. However, it occurs within the context of the medical device/biotech sector where stock options are a common form of executive compensation.

Related Party Transactions

• Cancellation of 65,542 stock options held by Director Lori Bisson by mutual agreement with the Company, with no consideration paid to Ms. Bisson.

Stakeholder Impact

• Shareholders: Could be viewed negatively as a director forfeits potential gains, possibly signaling a lack of confidence or a move to reduce dilution without a clear benefit.
• Management: The company benefits from fewer outstanding options, reducing potential future dilution, but the lack of consideration for the director could be a point of internal discussion.

Key Dates

Recommendation

The cancellation of a substantial number of stock options by a director without consideration is a notable event. While it reduces potential future dilution for shareholders, the lack of compensation for the director's forfeiture could be interpreted as a negative signal regarding the company's future prospects or the perceived value of the options. Investors should hold and monitor for further developments or broader financial disclosures to assess the underlying reasons and overall company health.

Keywords

Autonomix Medical, AMIX, SEC Form 4, Stock Options, Director Compensation, Insider Trading, Reverse Stock Split, Corporate Governance, Lori Bisson